316 related articles for article (PubMed ID: 11921656)
1. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
[No Abstract] [Full Text] [Related]
2. [Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].
Vetter C
MMW Fortschr Med; 2005 Mar; 147(13):10. PubMed ID: 15832752
[No Abstract] [Full Text] [Related]
3. [5-aminosalicylic acid and cancer prophylaxis?].
Thomsen OO
Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
[No Abstract] [Full Text] [Related]
4. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
[No Abstract] [Full Text] [Related]
5. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
[TBL] [Abstract][Full Text] [Related]
6. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
Fallingborg JF
Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
[TBL] [Abstract][Full Text] [Related]
7. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
8. [Value of therapy with 5-aminosalicylic acid in chemoprevention of colorectal carcinoma in ulcerative colitis].
Herfarth H; Schölmerich J
Z Gastroenterol; 2000 Nov; 38(11):923-5. PubMed ID: 11132541
[No Abstract] [Full Text] [Related]
9. [Colorectal cancer in inflammatory bowel disease].
Henriksen M; Moum B
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
[TBL] [Abstract][Full Text] [Related]
10. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
11. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
Herfarth H
Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
[TBL] [Abstract][Full Text] [Related]
12. [Ulcerative colitis. Cancer prevention].
Schmiegel W; Pox C; Kroesen A
Z Gastroenterol; 2004 Sep; 42(9):1014-8. PubMed ID: 15455276
[No Abstract] [Full Text] [Related]
13. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
Allgayer H; Kruis W
Clin Gastroenterol Hepatol; 2006 Apr; 4(4):521; author reply 521. PubMed ID: 16616360
[No Abstract] [Full Text] [Related]
15. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
16. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
Stange EF
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
[TBL] [Abstract][Full Text] [Related]
17. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?
Ardizzone S; Porro GB
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S238-9. PubMed ID: 18816705
[No Abstract] [Full Text] [Related]
18. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.
Sandborn WJ
Am J Gastroenterol; 2002 Dec; 97(12):2939-41. PubMed ID: 12492172
[No Abstract] [Full Text] [Related]
19. [Inflammatory bowel disease and colorectal cancer].
Hagymási K; Tulassay Z
Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
[TBL] [Abstract][Full Text] [Related]
20. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
